MSLN and neoplasm: Pretreatment with folate receptor beta-specific CAR-T cells prior to anti-mesothelin CAR-T cell therapy can modulate the tumor immune microenvironment and improve the effectiveness of anti-mesothelin CAR-T cells, which is conducive to better therapeutic effects.110